Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9299MR)

This product GTTS-WQ9299MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15466MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ3251MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ13404MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ1601MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ1628MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ7721MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ806MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11405MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW